Colorectal Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

 

Colorectal cancer, also known as colon cancer, appears in the colon or the rectum and is the third leading cause of cancer that develops slowly over several years. It usually begins as a non-cancerous polyp, an abnormal growth of tissue that lines the colon. Colorectal cancer can manifest as sporadic (70%), familial clustering (20%), and inherited syndrome (10%). Several risk factors are associated with colon cancer, including age, environment, diets with high animal fat, obesity, cigarette smoking, heavy alcohol consumption, hereditary, and history of inflammatory bowel disease. The most common type of colon cancer found in patients diagnosed is adenocarcinoma. The adenoma-carcinoma sequence is the base for colorectal cancer development, with a build-up of genetic alteration. The gatekeeper (gene that regulates growth) pathway accounts for approximately 85% of sporadic colorectal cancers and is the mechanism of carcinogenesis in FAP patients. Mutation of the tumor-suppressor gene APC is a crucial step in this process. Several other tumor-suppressor genes (such as DCC DPC4/Smad4, nm32, and p53) and oncogenes (e.g., c-myc, c-neu,c-src, c-erb-2, and K-ras) are also involved. Other types of colon cancer are rare such as carcinoid tumors (start in hormone-producing cells in the intestines), gastrointestinal stromal tumors (soft tissue sarcoma), and lymphoma (related to autoimmune that can begin in the colon).

• The incidence cases of Colorectal cancer range from 38 to 45 cases per 100,000 population in the USA.

Thelansis’s “Colorectal cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Colorectal cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Colorectal Cancer across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Colorectal Cancer  Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Colorectal Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032